Login
$LXRX
$1.79 +$0.00 (0.0%) Live

$LXRX SEC Filings

Filed On Filing
09 Nov 2026 Form 4: Exton Michael, Director

Bought 30,064 shares ($50K)

05 Nov 2026 10-Q
05 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 8-K: Results of Operations and Financial Condition

The Woodlands, Texas, November 5, 2026 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today reported financial results for the three months ended September 30, 2026, and provided an u...

14 Aug 2026 EFFECT
06 Aug 2026 S-3
06 Aug 2026 S-8
06 Aug 2026 10-Q
06 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 8-K: Results of Operations and Financial Condition

The Woodlands, Texas, August 6, 2026 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments.

04 Jun 2026 Form 4: Swain Judith L, Director

Received 89,312 shares by exercise or conversion

04 Jun 2026 Form 4: Sullivan Diane E., Director

Received 89,312 shares by exercise or conversion

04 Jun 2026 Form 4: Sobecki Christopher J, Director

Received 89,312 shares by exercise or conversion

04 Jun 2026 Form 4: Cheung Ivan, Director

Received 89,312 shares by exercise or conversion

04 Jun 2026 Form 4: Barker Sam L, Director

Received 89,312 shares by exercise or conversion

04 Jun 2026 Form 4: Amouyal Philippe, Director

Received 89,312 shares by exercise or conversion

04 Jun 2026 Form 4: Debbane Raymond, Director

Received 89,312 shares by exercise or conversion

08 May 2026 Form 4: Artal Participations S.a r.l., Director and 6 others

Received 20,421,735 shares by exercise or conversion · Granted 408,434.7 Series B Convertible Preferred Stock

08 May 2026 SCHEDULE 13D/A
07 May 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support